Table 1.
Baseline Characteristics of Patients With DM in the ACCELERATE Trial, Stratified by HbA1c
| Characteristic | Total (N=8145) | HbA1c, % | P Value | |||||
|---|---|---|---|---|---|---|---|---|
| <6.0 (N=1418) | 6.0–<6.5 (N=1620) | 6.5–<7.0 (N=1554) | 7.0–<7.5 (N=1111) | 7.5–<8.0 (N=792) | ≥8.0 (N=1650) | |||
| Age, y | 65.5±8.7 | 65.5±8.6 | 66.7±8.6 | 66.6±8.3 | 65.9±8.6 | 65.4±8.4 | 63.0±9.0 | <0.001 |
| Men, n (%) | 6218 (76.3) | 1131 (79.8) | 1268 (78.3) | 1173 (75.5) | 835 (75.2) | 605 (76.4) | 1206 (73.1) | <0.001 |
| White, n (%) | 6354 (78.4) | 1180 (83.5) | 1260 (78.3) | 1214 (78.5) | 875 (79.1) | 623 (79.4) | 1202 (73.2) | <0.001 |
| Body mass index, kg/m2 | 31.1±5.9 | 30.4±5.4 | 30.6±6.1 | 31.1±5.9 | 31.1±6.1 | 31.3±5.5 | 32.2±6.1 | <0.001 |
| Recent acute coronary syndrome, n (%) | 1269 (15.6) | 250 (17.6) | 249 (15.4) | 212 (13.6) | 159 (14.3) | 127 (16.0) | 272 (16.5) | 0.77 |
| Cerebral vascular disease, n (%) | 1735 (21.3) | 299 (21.1) | 342 (21.1) | 350 (22.5) | 250 (22.5) | 176 (22.2) | 318 (19.3) | 0.33 |
| Peripheral artery disease, n (%) | 1354 (16.6) | 212 (15.0) | 238 (14.7) | 261 (16.8) | 189 (17.0) | 144 (18.2) | 310 (18.8) | <0.001 |
| Coronary artery disease, n (%) | 7594 (93.2) | 1327 (93.6) | 1518 (93.7) | 1447 (93.1) | 1046 (94.1) | 736 (92.9) | 1520 (92.1) | 0.09 |
| Hypertension, n (%) | 7474 (91.8) | 1313 (92.6) | 1491 (92.0) | 1417 (91.2) | 1027 (92.4) | 732 (92.4) | 1494 (90.5) | 0.11 |
| Current smoker, n (%) | 1168 (14.3) | 160 (11.3) | 225 (13.9) | 234 (15.1) | 158 (14.2) | 123 (15.5) | 268 (16.2) | <0.001 |
| Prior myocardial infarction, n (%) | 4551 (59.9) | 832 (62.7) | 900 (59.2) | 833 (57.5) | 602 (57.5) | 441 (59.9) | 943 (62.0) | 0.92 |
| Prior percutaneous coronary intervention, n (%) | 5358 (70.5) | 927 (69.9) | 1088 (71.7) | 1003 (69.3) | 737 (70.5) | 512 (69.6) | 1091 (71.8) | 0.55 |
| Prior coronary artery bypass grafting, n (%) | 2518 (33.1) | 428 (32.2) | 501 (33.0) | 490 (33.8) | 359 (34.3) | 265 (36.0) | 475 (31.3) | 0.94 |
| Congestive heart failure, n (%) | 1249 (15.3) | 194 (13.7) | 208 (12.8) | 221 (14.2) | 207 (18.6) | 129 (16.3) | 290 (17.6) | <0.001 |
| Chronic obstructive pulmonary disease, n (%) | 883 (10.8) | 157 (11.1) | 177 (10.9) | 172 (11.1) | 116 (10.4) | 91 (11.5) | 170 (10.3) | 0.56 |
| Renal impairment, n (%) | 858 (10.5) | 113 (8.0) | 170 (10.5) | 186 (12.0) | 134 (12.1) | 93 (11.7) | 162 (9.8) | 0.13 |
| Baseline laboratory values | ||||||||
| Low‐density lipoprotein cholesterol, mg/dL | 80.0±27.4 | 78.7±27.2 | 79.8±26.2 | 79.3±27.1 | 79.3±25.2 | 78.5±27.1 | 83.3±30.3 | <0.001 |
| High‐density lipoprotein cholesterol, mg/dL | 44.2±11.3 | 45.7±11.7 | 45.2±11.3 | 45.1±11.5 | 43.9±11.3 | 42.5±10.5 | 42.2±10.8 | <0.001 |
| Triglyceride, mg/dL | 136 (99–186) | 121 (91–164) | 130 (97–177) | 134 (99–182) | 140 (102–188) | 144 (106–195) | 153 (111–218) | <0.001 |
| Apolipoprotein A‐I, mg/dL | 137.4±25.0 | 139.6±26.5 | 138.7±24.2 | 138.7±24.6 | 137.2±25.3 | 133.7±24.1 | 134.8±24.9 | <0.001 |
| Apolipoprotein B, mg/dL | 78.3±21.6 | 75.8±21.2 | 76.9±20.3 | 77.2±20.9 | 78.6±20.4 | 77.6±20.9 | 83.0±23.9 | <0.001 |
| Lipoprotein(a), nmol/L | 27 (10–100) | 29 (11–99) | 28 (11–104) | 29 (10–99) | 26 (10–105) | 25 (11–100) | 25 (9–90) | 0.33 |
| High‐sensitivity CRP, mg/L | 1.54 (0.76–3.42) | 1.22 (0.63–2.61) | 1.29 (0.66–2.91) | 1.52 (0.75–3.17) | 1.55 (0.76–3.41) | 1.68 (0.86–4.16) | 2.16 (1.01–4.76) | <0.001 |
| Medications, n (%) | ||||||||
| Statin | 7831 (96.1) | 1362 (96.1) | 1551 (95.7) | 1496 (96.3) | 1073 (96.6) | 761 (96.1) | 1588 (96.2) | 0.56 |
| High‐dose statin | 3427 (42.6) | 561 (40.0) | 675 (42.3) | 657 (42.8) | 459 (41.8) | 350 (45.0) | 725 (44.5) | 0.012 |
| Angiotensin‐converting enzyme inhibitor/angiotensin‐II receptor blocker | 6549 (80.4) | 1145 (80.7) | 1296 (80.0) | 1244 (80.1) | 875 (78.8) | 647 (81.7) | 1342 (81.3) | 0.48 |
| Aspirin | 6801 (83.5) | 1203 (84.8) | 1359 (83.9) | 1295 (83.3) | 916 (82.4) | 648 (81.8) | 1380 (83.6) | 0.20 |
| Antiglycemic medications, n (%) | ||||||||
| Any medication | 7182 (88.2) | 1083 (76.4) | 1326 (81.9) | 1390 (89.4) | 1037 (93.3) | 759 (95.8) | 1587 (96.2) | <0.001 |
| Insulin | 2391 (29.4) | 104 (7.3) | 208 (12.8) | 367 (23.6) | 387 (34.8) | 350 (44.2) | 975 (59.1) | <0.001 |
| Oral medication | 6313 (77.5) | 1032 (72.8) | 1258 (77.7) | 1270 (81.7) | 902 (81.2) | 627 (79.2) | 1224 (74.2) | 0.61 |
| Biguanide | 4894 (60.1) | 796 (56.1) | 985 (60.8) | 993 (63.9) | 689 (62.0) | 486 (61.4) | 945 (57.3) | 0.97 |
| Sulfonylurea | 2385 (29.3) | 263 (18.5) | 391 (24.1) | 437 (28.1) | 411 (37.0) | 312 (39.4) | 571 (34.6) | <0.001 |
| α‐Glucosidase inhibitor | 320 (3.9) | 30 (2.1) | 76 (4.7) | 61 (3.9) | 56 (5.0) | 34 (4.3) | 63 (3.8) | 0.09 |
| Thiazolidinedione | 296 (3.6) | 42 (3.0) | 61 (3.8) | 63 (4.1) | 43 (3.9) | 31 (3.9) | 56 (3.4) | 0.68 |
| Dipeptidyl peptidase‐4 inhibitor | 981 (12.0) | 116 (8.2) | 162 (10.0) | 200 (12.9) | 180 (16.2) | 109 (13.8) | 214 (13.0) | <0.001 |
| Other oral medication | 396 (4.9) | 39 (2.8) | 59 (3.6) | 65 (4.2) | 75 (6.8) | 51 (6.4) | 107 (6.5) | <0.001 |
Data are given as mean±SD or median (interquartile range), unless otherwise indicated. ACCELERATE indicates Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes; CRP, C‐reactive protein; DM, diabetes mellitus; HbA1c, hemoglobin A1c.